Status:

RECRUITING

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Lead Sponsor:

Pfizer

Conditions:

Menstrual Migraine

Eligibility:

FEMALE

18-45 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience ...

Eligibility Criteria

Inclusion Criteria:

  1. Participant has regular menstrual cycles ≥24 days and ≤34 days
  2. A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
  3. A history of menstrual migraine attacks of at least 3 months
  4. Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
  5. If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study

Exclusion Criteria:

  1. Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
  2. A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening
  3. History of retinal migraine, basilar migraine or hemiplegic migraine
  4. Current diagnosis of schizophrenia, bipolar, or borderline personality disorder
  5. Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea

Key Trial Info

Start Date :

March 11 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 30 2027

Estimated Enrollment :

723 Patients enrolled

Trial Details

Trial ID

NCT06641466

Start Date

March 11 2025

End Date

March 30 2027

Last Update

April 16 2026

Active Locations (122)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 31 (122 locations)

1

Mayo Clinic Hospital

Phoenix, Arizona, United States, 85054

2

Mayo Clinic Specialty Building

Phoenix, Arizona, United States, 85054

3

Mayo Clinic Arizona

Scottsdale, Arizona, United States, 85259

4

Hope Clinical Research, Inc.

Canoga Park, California, United States, 91303

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | DecenTrialz